表紙
市場調查報告書

雌激素受體:開發中產品分析

Estrogen Receptor - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 557377
出版日期 內容資訊 英文 91 Pages
訂單完成後即時交付
價格
雌激素受體:開發中產品分析 Estrogen Receptor - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 91 Pages
簡介

本報告提供以雌激素受體為標的之治療藥開發平台現狀及最新更新之各開發階段比較分析,提供涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

雌激素受體;概要

雌激素受體;治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Arvinas Inc
  • AstraZeneca Plc
  • Atossa Genetics Inc
  • Chamaeleo Pharma NV
  • EndoCeutics Inc
  • Genentech Inc
  • H3 Biomedicine Inc
  • Mithra Pharmaceuticals SA
  • Novartis AG
  • Nuevolution AB
  • Shenogen Pharma Group Ltd

藥物簡介

暫停中的產品

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2036TDB

Summary

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Estrogen receptor alpha (ERA) is a nuclear receptor that is activated by the sex hormone estrogen. It is encoded by the gene ESR1. It is involved in pathological processes including breast cancer, endometrial cancer, and osteoporosis. It decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displaces RELA/p65 and associated co-regulators from the promoter. It recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP.

Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) pipeline Target constitutes close to 27 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 5, 6, 7 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Central Nervous System, Women's Health and Male Health which include indications Breast Cancer, Metastatic Breast Cancer, Osteoporosis, Hormone Sensitive Breast Cancer, Alzheimer's Disease, Bipolar Disorder (Manic Depression), Carcinomas, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Demyelinating Diseases, Ductal Carcinoma In Situ, Endometrial Cancer, Endometriosis, Fallopian Tube Cancer, Hepatocellular Carcinoma, Male Hypogonadism, Melanoma, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Neuromyelitis Optica (Devic's Syndrome), Non-Small Cell Lung Cancer, Ovarian Cancer, Peritoneal Cancer, Prostate Cancer, Uterine Cancer and Vasomotor Symptoms of Menopause (Hot Flashes).

The latest report Estrogen Receptor - Pipeline Review, H2 2019, outlays comprehensive information on the Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1)
  • The report reviews Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Overview
  • Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Companies Involved in Therapeutics Development
  • Amgen Inc
  • Arvinas Inc
  • AstraZeneca Plc
  • Atossa Genetics Inc
  • Avivia BV
  • Eagle Pharmaceuticals Inc
  • Endece LLC
  • EndoCeutics Inc
  • Evestra Inc
  • H3 Biomedicine Inc
  • Helixmith Co Ltd
  • Huons Co Ltd
  • Jina Pharmaceuticals Inc
  • Novartis AG
  • Shenogen Pharma Group Ltd
  • TTC Oncology LLC
  • Zenopharm LLC
  • Zentalis Pharmaceuticals LLC
  • Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Drug Profiles
  • (bazedoxifene acetate + cholecalciferol) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • acolbifene + prasterone - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ARV-471 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dehydrodiconiferyl alcohol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • EC-372 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Endoxifen - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ERX-11 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fosfestrol - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fulvestrant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fulvestrant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • fulvestrant - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • H-3B5942 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • H-3B6545 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • K-07 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Libidua - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Loseasonique - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • NDC-1308 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize ESR1 and VEGFR2 for Breast Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize ER Alpha for Breast Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize ER-Alpha for Breast Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize ER-Alpha for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize Estrogen Receptor Alpha for Breast Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SNG-1153 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SNG-8023 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SR-16234 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TTC-352 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ZB-716 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ZNc-5 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Dormant Products
  • Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Discontinued Products
  • Estrogen Receptor (ER Alpha or Estradiol Receptor or Nuclear Receptor Subfamily 3 Group A Member 1 or NR3A1 or ESR1) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 09, 2019: Eagle Pharmaceuticals commences dosing in pilot study for novel estrogen receptor antagonist product candidate
  • Oct 24, 2019: Arvinas reports initial Phase I data for two cancer assets
  • Oct 17, 2019: Arvinas to present initial data from ARV-471 at the 2nd Targeted Protein Degradation Summit
  • Oct 16, 2019: Atossa Genetics receives IRB approval for phase 2 breast cancer study using intraductal technology
  • Aug 27, 2019: Arvinas announces the initiation of patient dosing in a first-in-human phase 1 study of ARV-471, an estrogen receptor-targeting PROTAC protein degrader
  • Aug 05, 2019: Eagle Pharmaceuticals announces Clinical Development Plan of innovative product intended to deliver maximum Estrogen Receptor inhibition in patients with Estrogen Receptor (ER)-Positive Breast Cancer
  • Jun 25, 2019: Arvinas receives authorization to proceed for ARV-471, a PROTAC Protein Degrader to treat patients with Locally Advanced or Metastatic ER+ / HER2- Breast Cancer
  • May 16, 2019: Eisai Presents data on H3B-6545 at 55th ASCO Annual Meeting
  • Mar 27, 2019: Combo better for HR+ breast cancer patients
  • Dec 07, 2018: Arvinas presents preclinical data on protein degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS)
  • Oct 30, 2018: Eagle Pharmaceuticals announces results of study for fulvestrant
  • Oct 20, 2018: New option for women with advanced breast cancer resistant to hormone therapy
  • Jul 10, 2018: Cancer Discovery Features H3 Biomedicine Paper Highlighting Effects of Selective Estrogen Receptor Covalent Antagonists (SERCAs) in ERa Wild-Type and Mutant Breast Cancer Models
  • Jun 01, 2018: ENDECE Attending 2018 Bio International in Boston
  • Mar 26, 2018: Mayne Pharma Launches Generic Quartette in the U.S., Another Womens Health Product
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Amgen Inc, H2 2019
  • Pipeline by Arvinas Inc, H2 2019
  • Pipeline by AstraZeneca Plc, H2 2019
  • Pipeline by Atossa Genetics Inc, H2 2019
  • Pipeline by Avivia BV, H2 2019
  • Pipeline by Eagle Pharmaceuticals Inc, H2 2019
  • Pipeline by Endece LLC, H2 2019
  • Pipeline by EndoCeutics Inc, H2 2019
  • Pipeline by Evestra Inc, H2 2019
  • Pipeline by H3 Biomedicine Inc, H2 2019
  • Pipeline by Helixmith Co Ltd, H2 2019
  • Pipeline by Huons Co Ltd, H2 2019
  • Pipeline by Jina Pharmaceuticals Inc, H2 2019
  • Pipeline by Novartis AG, H2 2019
  • Pipeline by Shenogen Pharma Group Ltd, H2 2019
  • Pipeline by TTC Oncology LLC, H2 2019
  • Pipeline by Zenopharm LLC, H2 2019
  • Pipeline by Zentalis Pharmaceuticals LLC, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Top 10 Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019